Press Room

Biotheranostics Announces Inclusion of Breast Cancer Index™ in the National Comprehensive Cancer Network (NCCN)
Breast Cancer Index (BCI) has reached an incredible milestone as a new standard of care ...
Biotheranostics appoints Mark D. Pegram, MD as Chief Medical Consultant for Breast Oncology
Biotheranostics' announces Mark D. Pegram, MD as a Chief Medical Consultant for Breast Oncology for Biotheranostics ...
Breast Cancer Index™ demonstrates its ability to predict preferential endocrine benefit irrespective of risk for HR+ early-stage breast cancer patients
Evidence demonstrating the ability of Breast Cancer Index to predict preferential endocrine benefit ...
Biotheranostics to premiere new data on Breast Cancer Index™ and prediction of endocrine therapy benefit at SABCS 2020
New data on Biotheranostics' Breast Cancer Index test will be highlighted ...
Biotheranostics' Breast Cancer Index™ IDEAL study expands clinical evidence for prediction of extended endocrine benefit to patients treated with aromatase inhibitors
Biotheranostics announces the publication of results from the IDEAL study ...
Biotheranostics CancerTYPE ID® aids in patient selection for immunotherapy
Biotheranostics announces the publication of a new study evaluating CancerTYPE ID® and its role in identifying subsets of patients ...
Biotheranostics to Present at the LifeSci Partners Summer Symposium
Biotheranostics, Inc., a leading healthcare provider in the oncology field with a suite of commercially available proprietary molecular diagnostic tests ...
Biotheranostics presents new studies of the Breast Cancer Index® at the 2020 ASCO conference
Biotheranostics announces several new studies demonstrating comprehensive validation and clinical utility of its Breast Cancer Index ...
Biotheranostics’ Breast Cancer Index® predicts benefit from two-and-a-half versus five years of extended endocrine therapy in HR+ breast cancer patients treated in the IDEAL trial
Novel evidence demonstrating the ability of Breast Cancer Index to predict preferential endocrine response in distinct subgroups ...
Biotheranostics Announces Chief Commercial Officer
On April 1, 2020, company veteran and Vice President of Sales, Matt Sargent, was promoted ...
Biotheranostics’ Pivotal Clinical Study of the Breast Cancer Index® featured on the cover of the Annals of Oncology
A pivotal clinical study validating Breast Cancer Index earns the distinction of being selected for the cover of the Annals of Oncology ... ...
Biotheranostics Launches Not Another Minute Campaign for its Breast Cancer Index® Test
Biotheranostics, Inc. announces the launch of its Not Another Minute campaign ...
Biotheranostics to Present New Data Expanding the Clinical Utility of Breast Cancer Index® at the 42nd Annual San Antonio Breast Cancer Symposium
Biotheranostics, Inc. announced today that several abstracts featuring updates on ongoing research and new data ...